We are studying whether adding mifamurtide to standard chemotherapy helps improve outcomes for patients with high-risk osteosarcoma. This trial is for individuals aged 2 to 50 who are newly diagnosed with this aggressive cancer.
Health conditions and diseases that the clinical trial is designed to study and treat.
High-risk osteosarcoma is a type of bone cancer that occurs in patients, particularly those under 50 years old, characterized by aggressive behavior and often diagnosed at an advanced stage, such as metastatic disease or with poor response to initial treatment.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.